NASDAQ:RVMD

Revolution Medicines Stock Insider Trading

Healthcare > Biotechnology

Buy RVMD

*Your capital is at risk

$155.99

+4.68 (+3.09%)

At Close: Jun 03, 2026

Revolution Medicines Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -56.46. In total, the insiders bought 1.73M and sold 485.44K RVMD shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-56.46
● Buy	1.73M shares
● Sell	485.44K shares
50% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Apr 15, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -56.46. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 07, 2026 Sell	Common Stock S-Sale	Horn Margaret A Chief Operating Officer	C-Suite Officer	53 096 Value: $5.31M
Jan 07, 2026 Buy	Common Stock M-Exempt	Horn Margaret A Chief Operating Officer	C-Suite Officer	51 406 Value: $2.18M
Jan 07, 2026 Buy	Common Stock M-Exempt	Horn Margaret A Chief Operating Officer	C-Suite Officer	23 594 Value: $703.1K
Jan 07, 2026 Sell	Common Stock S-Sale	Anders Jack Chief Financial Officer	C-Suite Officer	10 000 Value: $980.0K
Jan 07, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Anders Jack Chief Financial Officer	C-Suite Officer	10 000 Value: $424.5K
Dec 16, 2025 Sell	Common Stock S-Sale	Anders Jack Chief Financial Officer	C-Suite Officer	3 104 Value: $239.3K
Dec 16, 2025 Sell	Common Stock S-Sale	Horn Margaret A Chief Operating Officer	C-Suite Officer	4 847 Value: $372.3K
Dec 16, 2025 Sell	Common Stock S-Sale	Kelsey Stephen Michael See Remarks	Officer	5 447 Value: $418.4K
Dec 16, 2025 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	15 394 Value: $1.18M
Dec 16, 2025 Sell	Common Stock S-Sale	Cislini Jeff General Counsel	Officer	2 688 Value: $206.5K
Nov 25, 2025 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	3 000 Value: $225.0K
Nov 25, 2025 Buy	Common Stock M-Exempt	Anders Jack Chief Financial Officer	C-Suite Officer	5 418 Value: $92.1K
Nov 25, 2025 Sell	Common Stock S-Sale	Anders Jack Chief Financial Officer	C-Suite Officer	5 418 Value: $400.9K
Nov 25, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Anders Jack Chief Financial Officer	C-Suite Officer	5 418 Value: $92.1K
Nov 25, 2025 Buy	Common Stock M-Exempt	Goldsmith Mark A See Remarks	Officer	60 000 Value: $245.4K
Nov 25, 2025 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	60 000 Value: $4.50M
Nov 25, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Goldsmith Mark A See Remarks	Officer	60 000 Value: $245.4K
Nov 18, 2025 Buy	Common Stock M-Exempt	Goldsmith Mark A See Remarks	Officer	20 000 Value: $81.8K
Nov 18, 2025 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	20 000 Value: $1.41M
Nov 18, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Goldsmith Mark A See Remarks	Officer	20 000 Value: $81.8K
Nov 18, 2025 Buy	Common Stock M-Exempt	Cislini Jeff General Counsel	Officer	13 388 Value: $568.3K
Nov 18, 2025 Sell	Common Stock S-Sale	Cislini Jeff General Counsel	Officer	13 388 Value: $939.0K
Nov 18, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Cislini Jeff General Counsel	Officer	13 388 Value: $568.3K
Nov 12, 2025 Buy	Common Stock M-Exempt	Goldsmith Mark A See Remarks	Officer	20 000 Value: $81.8K
Nov 12, 2025 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	20 000 Value: $1.30M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT REVOLUTION MEDICINES INC.

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells...

Read Full Profile Here